Boston Life Sciences, Inc. to Participate in the 2007 BIO CEO & Investor Conference
07 Febbraio 2007 - 4:28PM
PR Newswire (US)
HOPKINTON, Mass., Feb. 7 /PRNewswire-FirstCall/ -- Boston Life
Sciences, Inc. (NASDAQ:BLSI) today announced that Peter Savas,
Chairman and Chief Executive Officer of Boston Life Sciences, Inc.,
will be presenting a Company update at the BIO CEO & Investor
Conference on Tuesday, February 13, 2007 from 10:30 am - 11:10 am
EST. The conference is being held from February 12-14 at the
Waldorf-Astoria in New York City, NY. BLSI also announced that Mark
Hurtt, Chief Medical Officer of Boston Life Sciences, Inc., will be
participating on a panel at the BIO CEO & Investor Conference
titled "CNS: Parkinson's Disease - Biotech Breakthroughs", which
will run from 9:30 am - 10:55 am EST on Monday, February 12. This
panel will explore technologies that could enable early and
accurate diagnosis and identify an "at risk" population as well as
emerging therapies focused on currently untreated symptoms and
novel, potentially disease-modifying therapies. The Boston Life
Sciences Company presentation on February 13th will be available by
webcast. Access to the webcast will be available within the
Investor Relations section of the Boston Life Sciences website at
http://www.bostonlifesciences.com/. About Boston Life Sciences,
Inc. Boston Life Sciences, Inc. (BLSI) is engaged in the research
and clinical development of diagnostic and therapeutic products for
central nervous system (CNS) disorders. ALTROPANE(R) molecular
imaging agent is in Phase III clinical trials for the diagnosis of
Parkinson's Disease (PD) and Phase II clinical trials for the
diagnosis of Attention Deficit Hyperactivity Disorder (ADHD).
Cethrin(R), a recombinant-protein-based drug designed to promote
nerve repair after acute spinal cord injury, has reported positive
interim results in a Phase I/IIa clinical trial. The company's
research and pre-clinical CNS programs include Inosine for the
treatment of spinal cord injury and stroke, a DAT blocker for the
treatment of Parkinson's disease, and a second generation
technetium-based molecular imaging agent for PD and ADHD. BLSI's
current research collaborations include Harvard Medical School and
Children's Hospital Boston. Contact: Meredith Patin -- 508-497-2360
ext 239 Boston Life Sciences, Inc. DATASOURCE: Boston Life
Sciences, Inc. CONTACT: Meredith Patin of Boston Life Sciences,
Inc., +1-508-497-2360, ext 239, or Web site:
http://www.bostonlifesciences.com/
Copyright
Grafico Azioni Boston Life Sciences (NASDAQ:BLSI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Boston Life Sciences (NASDAQ:BLSI)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Boston Life Sciences (MM) (NASDAQ): 0 articoli recenti
Più Boston Life Sciences (MM) Articoli Notizie